Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
2.

Anaplastic Thyroid Carcinoma, Version 2.2015.

Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50.

3.

Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.

Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V.

Diabetes Technol Ther. 2014 Dec;16(12):874-9. doi: 10.1089/dia.2014.0115. Epub 2014 Oct 16.

4.

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

Busaidy NL, Cabanillas ME.

J Thyroid Res. 2012;2012:618985. doi: 10.1155/2012/618985. Epub 2012 Feb 28.

Supplemental Content

Loading ...
Support Center